Equities

Onconetix Inc

Onconetix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.74
  • Today's Change-0.02 / -1.14%
  • Shares traded40.84k
  • 1 Year change-87.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4.55261.93
Total Receivables, Net0.150.040.15
Total Inventory0.36----
Prepaid expenses0.770.470.23
Other current assets, total--00.76
Total current assets5.84263.07
Property, plant & equipment, net0.210.010.01
Goodwill, net56----
Intangibles, net25----
Long term investments------
Note receivable - long term------
Other long term assets----0
Total assets88263.08
LIABILITIES
Accounts payable5.301.500.58
Accrued expenses2.272.411.06
Notes payable/short-term debt9.6200
Current portion long-term debt/capital leases------
Other current liabilities, total0.000.01--
Total current liabilities173.921.64
Total long term debt0.1200
Total debt9.7400
Deferred income tax3.07----
Minority interest7.01----
Other liabilities, total1.49--0
Total liabilities293.921.64
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital49427.40
Retained earnings (accumulated deficit)(57)(19)(5.96)
Treasury stock - common(0.63)(0.57)--
Unrealized gain (loss)------
Other equity, total2.38----
Total equity59221.45
Total liabilities & shareholders' equity88263.08
Total common shares outstanding0.560.380.28
Treasury shares - common primary issue0.010.010
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.